Transgene SA (TNG.PA)
EUR 0.71
(-1.8%)
EUR 0.71
(-1.8%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -27.02 Million EUR | -11.54% |
| 2022 | -28.21 Million EUR | -83.16% |
| 2021 | -23.55 Million EUR | -16.32% |
| 2020 | -20.44 Million EUR | 8.09% |
| 2019 | -22.09 Million EUR | -243.18% |
| 2018 | 2.84 Million EUR | 136.71% |
| 2017 | -29.5 Million EUR | -40.75% |
| 2016 | -20.38 Million EUR | 23.01% |
| 2015 | -34.71 Million EUR | 30.27% |
| 2014 | -37.4 Million EUR | -1.76% |
| 2013 | -38.26 Million EUR | 2.62% |
| 2012 | -39.37 Million EUR | 6.56% |
| 2011 | -40.16 Million EUR | -30.74% |
| 2010 | -32.19 Million EUR | -36.55% |
| 2009 | -25.12 Million EUR | -28.89% |
| 2008 | -18.29 Million EUR | -255.3% |
| 2007 | -5.14 Million EUR | 75.4% |
| 2006 | -20.92 Million EUR | 0.0% |
| 2004 | -20.24 Million EUR | 0.24% |
| 2003 | -20.38 Million EUR | -7.64% |
| 2002 | -19.03 Million EUR | 4.16% |
| 2001 | -21.27 Million EUR | 14.02% |
| 2000 | -22.88 Million EUR | -15.07% |
| 1999 | -19.88 Million EUR | -29.01% |
| 1998 | -37.06 Million EUR | 3.64% |
| 1997 | -15.99 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -18.54 Million EUR | 0.0% |
| 2023 Q1 | -7.48 Million EUR | 57.2% |
| 2023 Q4 | -6.73 Million EUR | 0.0% |
| 2023 Q3 | -6.73 Million EUR | 60.07% |
| 2023 Q2 | -16.86 Million EUR | -125.17% |
| 2023 FY | - EUR | -11.54% |
| 2022 Q2 | -17.78 Million EUR | -154.19% |
| 2022 Q1 | -6.99 Million EUR | 39.7% |
| 2022 Q4 | -17.49 Million EUR | -146.1% |
| 2022 FY | - EUR | -83.16% |
| 2022 Q3 | -7.1 Million EUR | 60.03% |
| 2021 Q3 | -4.36 Million EUR | 72.97% |
| 2021 FY | - EUR | -16.32% |
| 2021 Q2 | -16.14 Million EUR | -158.06% |
| 2021 Q4 | -11.6 Million EUR | -165.88% |
| 2021 Q1 | -6.25 Million EUR | 58.66% |
| 2020 Q1 | -5.26 Million EUR | 62.92% |
| 2020 Q4 | -15.13 Million EUR | -149.94% |
| 2020 Q3 | -6.05 Million EUR | 56.78% |
| 2020 Q2 | -14.01 Million EUR | -166.17% |
| 2020 FY | - EUR | 8.09% |
| 2019 Q4 | -14.19 Million EUR | -177.56% |
| 2019 Q3 | -5.11 Million EUR | 67.72% |
| 2019 FY | - EUR | -243.18% |
| 2019 Q1 | -6.16 Million EUR | 9.56% |
| 2019 Q2 | -15.84 Million EUR | -157.17% |
| 2018 FY | - EUR | 136.71% |
| 2018 Q1 | -6.19 Million EUR | -19.01% |
| 2018 Q2 | -6.19 Million EUR | 0.0% |
| 2018 Q4 | -6.81 Million EUR | 0.0% |
| 2018 Q3 | -6.81 Million EUR | -10.02% |
| 2017 Q3 | -5.2 Million EUR | 33.6% |
| 2017 Q1 | -7.83 Million EUR | -46.18% |
| 2017 Q2 | -7.83 Million EUR | 0.0% |
| 2017 FY | - EUR | -40.75% |
| 2017 Q4 | -5.2 Million EUR | 0.0% |
| 2016 Q2 | -4.83 Million EUR | 0.0% |
| 2016 Q1 | -4.83 Million EUR | 22.06% |
| 2016 Q3 | -5.36 Million EUR | -10.93% |
| 2016 FY | - EUR | 23.01% |
| 2016 Q4 | -5.36 Million EUR | 0.0% |
| 2015 Q3 | -6.19 Million EUR | 6.24% |
| 2015 Q2 | -6.61 Million EUR | 0.0% |
| 2015 Q4 | -6.19 Million EUR | 0.0% |
| 2015 FY | - EUR | 30.27% |
| 2015 Q1 | -6.61 Million EUR | -3.15% |
| 2014 FY | - EUR | -1.76% |
| 2014 Q4 | -6.41 Million EUR | 0.0% |
| 2014 Q3 | -6.41 Million EUR | 31.0% |
| 2014 Q2 | -9.29 Million EUR | 0.0% |
| 2014 Q1 | -9.29 Million EUR | -6.61% |
| 2013 Q2 | -10.42 Million EUR | 0.0% |
| 2013 FY | - EUR | 2.62% |
| 2013 Q4 | -8.71 Million EUR | 0.0% |
| 2013 Q1 | -10.42 Million EUR | -8.16% |
| 2013 Q3 | -8.71 Million EUR | 16.37% |
| 2012 Q4 | -9.63 Million EUR | 0.0% |
| 2012 Q3 | -9.63 Million EUR | 0.0% |
| 2012 FY | - EUR | 6.56% |
| 2011 FY | - EUR | -30.74% |
| 2010 FY | - EUR | -36.55% |
| 2009 FY | - EUR | -28.89% |
| 2008 FY | - EUR | -255.3% |
| 2007 FY | - EUR | 75.4% |
| 2006 FY | - EUR | 0.0% |
| 2005 Q2 | -4.92 Million EUR | -585.69% |
| 2005 Q1 | 1.01 Million EUR | 104.32% |
| 2004 Q2 | -5.25 Million EUR | 6.69% |
| 2004 Q1 | -5.62 Million EUR | 14.74% |
| 2004 Q3 | 832.52 Thousand EUR | 115.85% |
| 2004 Q4 | -23.47 Million EUR | -2919.17% |
| 2004 FY | - EUR | 0.24% |
| 2003 FY | - EUR | -7.64% |
| 2003 Q4 | -6.6 Million EUR | -43.72% |
| 2003 Q2 | -5.4 Million EUR | -5.17% |
| 2003 Q3 | -4.59 Million EUR | 15.06% |
| 2003 Q1 | -5.14 Million EUR | -5.89% |
| 2002 Q4 | -4.85 Million EUR | -0.11% |
| 2002 FY | - EUR | 4.16% |
| 2002 Q1 | -5.4 Million EUR | 3.87% |
| 2002 Q2 | -5.21 Million EUR | 3.38% |
| 2002 Q3 | -4.85 Million EUR | 7.03% |
| 2001 Q3 | -5.25 Million EUR | 12.26% |
| 2001 Q1 | -5.83 Million EUR | -12.67% |
| 2001 FY | - EUR | 14.02% |
| 2001 Q4 | -5.61 Million EUR | -6.82% |
| 2001 Q2 | -5.99 Million EUR | -2.64% |
| 2000 Q2 | -4.34 Million EUR | 38.52% |
| 2000 Q4 | -5.18 Million EUR | 35.63% |
| 2000 FY | - EUR | -15.07% |
| 2000 Q3 | -8.05 Million EUR | -85.18% |
| 2000 Q1 | -7.07 Million EUR | 72.01% |
| 1999 Q3 | 751.18 Thousand EUR | -40.41% |
| 1999 FY | - EUR | -29.01% |
| 1999 Q4 | -25.26 Million EUR | -3463.79% |
| 1999 Q1 | 1.48 Million EUR | 105.89% |
| 1999 Q2 | 1.26 Million EUR | -14.94% |
| 1998 FY | - EUR | 3.64% |
| 1998 Q1 | 7.94 Million EUR | 0.0% |
| 1998 Q2 | 646.03 Thousand EUR | -91.87% |
| 1998 Q3 | 427.27 Thousand EUR | -33.86% |
| 1998 Q4 | -25.14 Million EUR | -5986.12% |
| 1997 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -721.398% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 79.713% |
| Adocia SA | -22.73 Million EUR | -18.881% |
| Aelis Farma SA | -6.34 Million EUR | -325.776% |
| Biophytis S.A. | -13.8 Million EUR | -95.769% |
| Advicenne S.A. | -6.24 Million EUR | -332.799% |
| genOway Société anonyme | 6.35 Million EUR | 525.525% |
| IntegraGen SA | -52.5 Thousand EUR | -51371.344% |
| Medesis Pharma S.A. | -3.84 Million EUR | -602.856% |
| Neovacs S.A. | -8.44 Million EUR | -219.828% |
| NFL Biosciences SA | -4.04 Million EUR | -567.374% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 37359.065% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -840.462% |
| Sensorion SA | -22.31 Million EUR | -21.109% |
| Theranexus Société Anonyme | -7.38 Million EUR | -265.82% |
| TME Pharma N.V. | -5.07 Million EUR | -432.808% |
| Valbiotis SA | -6.95 Million EUR | -288.555% |
| TheraVet SA | -517.33 Thousand EUR | -5123.684% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -42.863% |
| argenx SE | -199.5 Million EUR | 86.455% |
| BioSenic S.A. | -6.79 Million EUR | -297.646% |
| Celyad Oncology SA | -7.76 Million EUR | -248.113% |
| DBV Technologies S.A. | -79.53 Million EUR | 66.021% |
| Galapagos NV | 51.03 Million EUR | 152.95% |
| Genfit S.A. | -28.05 Million EUR | 3.661% |
| GeNeuro SA | -14.31 Million EUR | -88.745% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -80.401% |
| Innate Pharma S.A. | -7.57 Million EUR | -256.611% |
| Inventiva S.A. | -101.84 Million EUR | 73.466% |
| MaaT Pharma SA | -19.74 Million EUR | -36.9% |
| MedinCell S.A. | -20.04 Million EUR | -34.81% |
| Nanobiotix S.A. | -34.01 Million EUR | 20.562% |
| Onward Medical N.V. | -35.23 Million EUR | 23.301% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -509.561% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | -16.152% |
| Oxurion NV | -16.72 Million EUR | -61.54% |
| Pharming Group N.V. | 4.98 Million EUR | 642.545% |
| Poxel S.A. | -12.17 Million EUR | -121.89% |
| GenSight Biologics S.A. | -21.73 Million EUR | -24.363% |
| Financière de Tubize SA | 184.57 Thousand EUR | 14741.52% |
| UCB SA | 1.26 Billion EUR | 102.13% |
| Valneva SE | -64.51 Million EUR | 58.113% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 4.687% |